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EPIDEMIOLOGY AND PREVENTION
Limiting Cumulative HIV Viremia Copy-Years by Early
Treatment Reduces Risk of AIDS and Death
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Heiner C. Bucher, MD, MPH,§ Inma Jarrin, PhD,k¶ Santiago Moreno, MD,#
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Background: Viremia copy-years (VCY), a time-updated measure of
cumulative HIV exposure, predicts AIDS/death; although its utility in
deciding when to start combination antiretroviral therapy (cART)
remains unclear. We aimed to assess the impact of initiating versus
deferring cART on risk of AIDS/death by levels of VCY both
independent of and within CD4 cell count strata $500 cells per
cubic millimeter.
Methods: Using Concerted Action on Seroconversion to AIDS and
Death in Europe (CASCADE) data, we created a series of nested
“trials” corresponding to consecutive months for individuals $16
years at seroconversion after 1995 who were cART-naive and AIDS-
free. Pooling across all trials, time to AIDS/death by CD4, and VCY
strata was compared in those initiating vs. deferring cART using Cox
models adjusted for: country, sex, risk group, seroconversion year,
age, time since last HIV-RNA, and current CD4, VCY, HIV-RNA,
and mean number of previous CD4/HIV-RNA measurements/year.
Results: Of 9353 individuals, 5312 (57%) initiated cART and 486
(5%) acquired AIDS/died. Pooling CD4 strata, risk of AIDS/death
associated with initiating vs. deferring cART reduced as VCY
increased. In patients with high CD4 cell counts, $500 cells per
cubic millimeter, there was a trend for a greater reduction for those
initiating vs. deferring with increasing VCY (P = 0.09), with the
largest beneﬁt in the VCY $100,000 copy-years/mL group [hazard
ratio (95% CI) = 0.41 (0.19 to 0.87)].
Conclusions: For individuals with CD4 $500 cells per cubic
millimeter, limiting the cumulative HIV burden to ,100,000 copy-
years/mL through cART may reduce the risk of AIDS/death.
Key Words: viremia copy-years, seroconverters, when to start,
cART initiation, CD4 cell count, HIV-RNA
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INTRODUCTION
Although CD4 cell counts are used routinely to monitor
adults with HIV infection, viral loads also have an important role
in the monitoring and staging of adults with HIV.1,2 One or 2
values of an individual’s viral load are often used to determine
combination antiretroviral therapy (cART) failure, their risk of
transmitting HIV to others, and to tailor ﬁrst-line cART
regimens.3–5 However, assessment of an individual’s viral load
at a single point in time fails to capture cumulative exposure to
HIV replication which may have been over a period of 10 years
or more. Several investigators have proposed that a measure of
cumulative viral burden might provide useful additional infor-
mation and, in particular, a measurement of viremia copy-years
(VCY) has been proposed.6 VCY is akin to cigarette pack-years
when assessing exposure to tobacco; A VCY of 1000 copy-
years/mL is the equivalent to an individual having a viral load of
1000 copies per milliliter for an entire year or a viral load of 500
copies per milliliter for 2 years. The measurement of VCY has
been shown to predict death and AIDS in both the absence6 and
presence7,8 of cART, independently of the individual’s most
recent CD4 count and viral load. This independent association
suggests that cumulative HIV burden is associated with an
increased risk of development of clinical events through
mechanisms other than immunodeﬁciency.
United States guidelines recommend immediate cART
initiation, regardless of CD4 cell count5,9 due to evidence that
exposure to uncontrolled viremia is associated with an increased
risk of death, AIDS, and non-AIDS events.5,10–12 The START
(Starting Antiretroviral Treatment Early Improves Outcomes for
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HIV-Infected Individuals) trial has recently reported that waiting
to initiate cART until CD4 ,350 cells per cubic millimeter
increases the likelihood of serious illness or death compared with
immediate initiation.13 VCY serves as a measurement of
cumulative exposure to HIV, and so it is important to determine
whether VCY contributes to the likelihood of illness and death
and whether cART initiation before the accrual of VCY could
help optimize clinical and public health HIV outcomes.
Randomized trials are unlikely to be conducted to
determine whether accrual of viremia VCY before cART
initiation increases mortality because of the difﬁculty and
expertise in enrolling participants soon after seroconversion,
and because cART is now recommended in many asymptomatic
populations. In addition, there is substantial potential for lead-
time bias in analyses using VCY because of variability in the
extent of HIV replication an individual will have been exposed to
previous enrollment into care. One way to limit this bias is to
restrict analyses to participants with serial viral load measure-
ments since a known seroconversion date; such data are available
from the Concerted Action on Seroconversion to AIDS and
Death in Europe (CASCADE) Collaboration, an international
multicenter collaboration of data from persons with well-
estimated dates of HIV seroconversion. Previous analyses of
CASCADE data have shown a protective effect of initiating
cART on AIDS/death at CD4 ,500 cells per cubic millimeter
[hazard ratio (HR) 0.59 (95% CI: 0.43 to 0.81) and HR 0.75
(0.49–1.14) in CD4 cell strata 200–349 and 350–499, respec-
tively], but no evidence for a reduction in risk at CD4$500 cells
per cubic millimeter [HR 1.10 (0.67–1.79)].14 Here we examine
the effect of initiating or deferring cART at different levels of
VCY on HIV disease progression. We investigate whether or not
individuals with CD4 $500 cells per cubic millimeter but high
VCY would beneﬁt from starting cART.
METHODS
Study Population
Data from CASCADE in EuroCoord (www.EuroCoord.
net) 2013 data update were used for this analysis.15 Brieﬂy,
CASCADE is a cohort collaboration of 29 cohorts of individ-
uals with well-estimated dates of HIV seroconversion from
Europe (94%), Australia (2%), Canada (0.5%), and Sub-Saharan
Africa (3%). Date of seroconversion is estimated as the midpoint
between the last negative and ﬁrst positive HIV antibody test
results with a maximum of 3 years between the test dates (85%),
laboratory evidence of acute seroconversion (real-time poly-
merase chain reaction positivity of incomplete Western blot)
(13%), the date of seroconversion illness with a negative and
positive test no more than 3 years apart (2%), or by a probability
distribution to determine the most likely date of transmission for
men with hemophilia infected with HIV after transfusion with
clotting factor concentrates (,1% of the sample).
All cohorts contributing to CASCADE received ethical
approval from their individual ethics review boards.
Adults ($16 years old) seroconverting in the cART era
(post 1995) were included provided they had at least 1 HIV-
RNA measurement between 4 and 12 months after seroconver-
sion. Two Sub-Saharan African cohorts were excluded from this
analysis as their CD4 cell count and cART initiation patterns are
different from those in industrialized country cohorts.16
Study Design
We created a series of sequential nested “trials”
corresponding to consecutive months of follow-up beginning
4 months after seroconversion, where each month represents
the baseline month for a new trial (Fig. 1). As described
previously, this approach allows appropriate adjustment for
time-dependent confounding.17,18 We created new trials with
all eligible individuals for each month between January 1996
and May 2013. Individuals were eligible for a trial if they
were cART-naive before the baseline month, had a CD4 or
HIV-RNA measurement 12 months before the baseline
month, and were AIDS-free until the end of the baseline
month. Time to AIDS/death was compared in those who
initiated cART in each baseline month versus those who
deferred, pooling across all trials.
AIDS events in the ﬁrst year of seroconversion were not
considered as disease progression outcomes, but rather as
severe seroconversion illness. In addition, invasive candidi-
asis was not considered an outcome in this analysis as it is
typically less severe and associated with longer survival
compared with other AIDS-deﬁning conditions.19–22
Viremia Measurements
If HIV-RNA could be continuously measured within an
individual from seroconversion [with the viral load distribu-
tion at any time t called as V(t)], then VCY would be
calculated as the area under the HIV-RNA curve, or the
integral of HIV-RNA from seroconversion to time t = T.
VCY ¼
ZT
SC
VðtÞdt:
However, in practice, we do not have continuously measured
viral loads, but rather snapshots of HIV-RNA measurements for
each individual at irregularly spaced intervals (usually approxi-
mately 3 monthly). The best approximation to the integral with
the data available can be obtained through use of the trapezoidal
rule, which is how we approximated VCY for the remainder of
this analysis. At any given time point, J, say, VCY(J) is given
by:VCYðJÞ ¼ PJj¼1 tðjÞ2tðj21Þ∗V ðjÞþVðj21Þ2 . We examined
HIV-RNA data for implausible values and identiﬁed 3 individ-
uals whose HIV-RNA dropped by factors of 4, 26, and 87
between consecutive measurements and without apparently
starting cART. These are far greater drops than would be
expected based on the known biological variation of HIV-
RNA.23,24 As all 3 individuals were recorded as having started
cART in the following month, we assumed that the date of cART
initiation had been incorrectly recorded, and reset the cART start
dates for these individuals to 1 month before that recorded.
To estimate HIV exposure equally for all individuals, we
removed HIV-RNA measurements taken in the ﬁrst 3 months of
seroconversion, as we were unlikely to capture the well-
documented peak in viremia shortly after seroconversion25 for
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all individuals. In addition, we assumed that HIV-RNA measure-
ments remained relatively stable over the period 4–12 months
(consistent with ﬁndings of the viral load stabilizing after the
initial peak in viremia), allowing us to make the assumption that
an individual’s ﬁrst available HIV-RNA over the period 4–12
months was equal to their HIV-RNA at month 4.
Data Analysis
We describe baseline characteristics between those who
initiated or deferred cART during the study period. We
estimated the HRs for initiating versus deferring cART by
levels of VCY (,10,000 copy-years/mL, $10,000–19,999
copy-years/mL, $20,000–49,999 copy-years/mL, $50,000–
99,999 copy-years/mL, $100,000 copy-year/mL) pooled
across and stratiﬁed by CD4 cell count strata (initiate at CD4
,350 cells/mm3 compared with initiate at higher values,$350
cells/mm3, and initiate at ,500 cells/mm3 compared with
initiate at higher values, $500 cells/mm3) using Cox pro-
portional hazards models. We adjusted for trial-independent
factors including country of care, sex, HIV transmission risk
group, seroconversion year, and trial-dependent factors of
current age, time since last HIV-RNA measurement, CD4,
VCY, HIV-RNA, and mean number of previous CD4/HIV-
RNA measurements per year. Trial-dependent factors were
ascertained before the baseline month to ensure they were
measured before the decision to initiate or defer cART in the
current month. Continuous variables were modeled using
restricted cubic splines, all with 3 knots with the exception of
current CD4 which was modeled with 5 knots.26 Most
individuals contributed to more than 1 trial, so we used a robust
variance estimator to account for within-person correlation. To
investigate whether a threshold existed where cART initiation
showed the most beneﬁt, we ﬁtted interactions between initiating
cART and VCY as a continuous variable with a 3-knot spline.
Furthermore, we investigated whether there was a ben-
eﬁt of incorporating other measures of viremia into the
decision about when to initiate cART, namely, current HIV-
RNA (most recent measurement), average HIV-RNA (mean
of all previous measurements), and maximum HIV-RNA
(maximum of all previous measurements). To compare results
between all HIV-RNA measurements with VCY, we used the
same inclusion criteria for all analyses. We used the Akaike27
information criteria (AIC), a measure of the relative quality of
statistical models which evaluates trade-off between model
complexity and goodness of ﬁt, to determine which measure
of viremia best ﬁts the data.
RESULTS
Baseline Characteristics
The CASCADE 2013 update contains information on
30,006 individuals, of whom 21,082 seroconverted in the cART
era, during or after 1996. Of those, we excluded 916 individuals
from African cohorts and 10,813 individuals without at least 1
cART-naive HIV-RNA measurement within 4–12 months of
seroconversion, leaving 9353 individuals in the analysis.
Among those seroconverting in the cART era (n =
21,082), men who have sex between men were slightly over-
represented in this analysis compared with those excluded (80%
vs. 62%) and those who likely acquired HIV through sex
between men and women were slightly underrepresented (9%
vs. 29%). Date of seroconversion was later in those included in
this analysis [November 2005 (July 2002–August 2008)] than in
those excluded [July 2004 (July 2000–March 2008)] explained
by availability of routine HIV-RNA measurements within the
cohorts. All other baseline characteristics were similar among
those included and excluded from this analysis (data not shown).
Of 9353 individuals, 5312 (57%) initiated cART, 326
(3%) acquired AIDS, and 160 (2%) died. Median [interquar-
tile range (IQR) [25th–75th percentile] follow-up was 4.1
(1.8, 7.2) years. Most individuals were men (85%), and
modes of HIV transmission included sex between men (71%),
sex between men and women (21%), injection drug use (4%),
and unknown (4%). Median (IQR) CD4 at cART initiation
was 342 (265, 450) cells per cubic millimeter and did not vary
by VCY category. Median (IQR) seroconversion age was 33
(27, 40) years between 1996 and 2013. Individuals contrib-
uted to a median (IQR) of 21 (13, 36) trials.
Individuals who initiated cART typically had much
lower CD4 cell counts and higher HIV-RNA values than
those deferring cART. Men were also more likely to defer in
the lower viral copy-years strata (Table 1).
FIGURE 1. A diagram of the “trials”
construction. Individuals are assessed
for eligibility at the beginning of each
month (respective trial baseline).
Each eligible individual is classified as
having initiated or deferred cART in
the baseline month. Time is mea-
sured from the beginning of the fol-
lowing month until AIDS, death, or
censoring for each eligible individual
(excluding any with an outcome
during the baseline month). Cox
proportional hazards models are
used to assess the effect of initiating
compared with deferring cART on
time to AIDS/death, pooled across all
trials.
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Pooling across CD4 cell count strata, HRs for the effect
of initiating cART compared with deferring on time to AIDS/
death signiﬁcantly decreased as VCY increased (P-trend ,
0.001). For example, at times when the VCY was in the range
10,000–20,000 copy-years/mL, there was only a modest 9%
reduction in the hazard of AIDS/death associated with
immediate initiation of cART compared with deferral
[HR = 0.91 (95% CI: 0.57 to 1.46)], whereas at times when
the VCY was .100,000 copy-years/mL, the estimated
reduction in risk of AIDS/death associated with immediate
versus deferred initiation was 56% [HR = 0.44 (95% CI: 0.35
TABLE 1. Baseline Characteristic for Individuals Who Initiated or Deferred cART by Levels of VCY
Characteristic Initiated cART Deferred cART
VCY , 10,000 copy-years/mL
“Trial” observations, N 651 50,349
Follow-up, median (IQR) person-years 3.3 (1.4, 6.8) 4.2 (2.1, 7.0)
Male, N (%) 398 (61) 38,869 (77)
Seroconversion year 2005 (2000, 2009) 2004 (2001, 2007)
Seroconversion age 30 (26, 37) 33 (27, 39)
CD4 cell count median (IQR), mm3 397 (291, 567) 637 (486, 826)
HIV-RNA copies/mL median (IQR) * 3.7 (3.2, 4.1) 3.4 (3.0, 3.8)
VCY median (IQR) * 3.6 (3.2, 3.8) 3.5 (3.0, 3.8)
VCY $ 10,000–19,999 copy-years/mL
Trial observations, N 488 22,825
Follow-up, median (IQR) person-years 3.0 (1.4, 6.0) 4.0 (2.0, 6.6)
Male, N (%) 382 (78) 19,348 (85)
Seroconversion year 2006 (2002, 2009) 2005 (2002, 2007)
Seroconversion age 33 (26, 40) 32 (27, 39)
CD4 cell count median (IQR), mm3 360 (282, 475) 553 (437, 707)
HIV-RNA copies/mL median (IQR) * 4.3 (3.9, 4.6) 4.1 (3.7, 4.4)
VCY median (IQR) * 4.2 (4.1, 4.2) 4.2 (4.1, 4.2)
VCY $ 20,000–49,999 copy-years/mL
Trial observations, N 1026 39,675
Follow-up, median (IQR) person-years 3.3 (1.4, 6.6) 3.9 (1.9, 6.5)
Male, N (%) 853 (83) 34,804 (88)
Seroconversion year 2006 (2001, 2008) 2004 (2002, 2007)
Seroconversion age 34 (28, 41) 33 (27, 39)
CD4 cell count median (IQR), mm3 355 (277, 466) 523 (417, 662)
HIV-RNA copies/mL median (IQR) * 4.6 (4.3, 4.9) 4.3 (3.9, 4.6)
VCY median (IQR) * 4.5 (4.4, 4.6) 4.5 (4.4, 4.6)
VCY $ 50,000–99,999 copy-years/mL
Trial observations, N 950 30,925
Follow-up, median (IQR) person-years 3.1 (1.4, 5.7) 3.8 (1.8, 6.2)
Male, N (%) 837 (88) 27,657 (89)
Seroconversion year 2005 (2002, 2008) 2004 (2002, 2006)
Seroconversion age 33 (27, 41) 33 (27, 39)
CD4 cell count median (IQR), mm3 340 (272, 440) 492 (393, 628)
HIV-RNA copies/mL median (IQR) * 4.8 (4.4, 5.1) 4.5 (4.2, 4.8)
VCY median (IQR) * 4.9 (4.8, 4.9) 4.8 (4.8, 4.9)
VCY $ 100,000 copy-years/mL
Trial observations, N 2102 44,581
Follow-up, median (IQR) person-years 3.5 (1.6, 5.6) 3.9 (1.8, 6.2)
Male, N (%) 1928 (92) 41,702 (94)
Seroconversion year 2005 (2002, 2007) 2004 (2001, 2006)
Seroconversion age 35 (29, 42) 33 (28, 40)
CD4 cell count median (IQR), mm3 320 (246, 411) 467 (370, 591)
HIV-RNA copies/mL median (IQR) * 5.2 (4.8, 5.5) 4.9 (4.5, 5.2)
VCY median (IQR) * 5.3 (5.2, 5.6) 5.3 (5.1, 5.5)
*Log10 copies per milliliter.
IQR, 25th and 75th percentiles.
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to 0.55)], Table 2. Among individuals initiating with CD4
$350 cells per cubic millimeter, there was a modest trend
(P = 0.11) toward a greater beneﬁt of immediate initiation of
cART (vs. deferral), although the results continued to suggest
some beneﬁt of earlier initiation among the group with VCY
.100,000 copy-years/mL [HR = 0.68 (95% CI: 0.49 to 0.94)],
Table 2. As expected among individuals initiating with CD4
,350 cells per cubic millimeter, immediate initiation was
beneﬁcial in all VCY categories (all HR , 1) (see Table,
Supplemental Digital Content, http://links.lww.com/QAI/A817).
Modeling initiation of cART by VCY as a continuous
variable showed the same trends as the categorical analysis,
Figure 2. No obvious threshold of copy-years was found;
however, pooling CD4 cell count categories, the upper bound
of the 95% CI ﬁrst fell below one when VCY passed 17,343
copies-years/mL, suggesting that among individuals with
VCY values above this threshold, immediate initiation of
cART may result in a reduction in the risk of AIDS/death.
Stratifying by CD4 cell count, in those with CD4 $350 cells
per cubic millimeter, the upper bound of the 95% CI fell
below one when VCY surpassed 52,826 copy-years/mL,
again suggesting that among individuals with high CD4 cell
counts and VCY values above this threshold, immediate
initiation of cART may result in a reduction in the risk
of AIDS/death.
Using a CD4 count threshold of 500 cells per cubic
millimeter showed similar results. For those with CD4 $500
cells per cubic millimeter, the greatest beneﬁt of initiation was
seen when VCY .100,000 copy-years/mL [HR = 0.41 (0.19,
0.87), P-trend = 0.09], Table 2. Modeling VCY continuously,
the upper bound of the 95% CI in those with CD4 $500 cells
per cubic millimeter fell below one when VCY surpassed 38,152
copy-years/mL. In those with a CD4 count,500 cells per cubic
millimeter, there was an overall beneﬁt of treatment initiation in
VCY categories .10,000 copy-years/mL (see Table, Supple-
mental Digital Content, http://links.lww.com/QAI/A817).
Other Measures of Viremia
Pooling CD4 strata, the HRs for the effect of initiating
cART on time to AIDS/death decreased as most recent HIV-
RNA increased (P-trend , 0.001) with the largest beneﬁt of
initiation seen when current HIV-RNA exceeded 100,000
copies/mL [HR = 0.45 (0.36, 0.57)]. Among individuals with
a CD4 count $350 cells per cubic millimeter, there was
a modest trend (P-trend = 0.08) for an increased beneﬁt of
immediate initiation (vs. deferral) as the current HIV-RNA
increased, with the largest beneﬁt of immediate initiation seen
if the current HIV-RNA was .100,000 copies/mL [HR =
0.65 (0.47, 0.89)], Table 2. Stratifying by CD4, there was
a beneﬁt of initiating versus deferring for all individuals with
CD4 ,350 cells per cubic millimeter regardless of current
HIV-RNA level, as expected from the VCY analysis. The
same trends were seen when modeling VCY and current HIV-
RNA continuously, Figure 2, and when considering average
and maximum viremia (data not shown).
Using a CD4 threshold of 500 cells per cubic millime-
ter, similar results were obtained for the average and
maximum viremia (data not shown).
Pooling CD4 strata, model ﬁt was best for VCY
(minimum AIC, 230115) compared with current (increase in
AIC = 238), average (increase in AIC = 124), and maximum
HIV-RNA (increase in AIC = 163). Maximum HIV-RNA ﬁts
the model best in the CD4 ,500 cells per cubic millimeter
strata (minimum AIC, 1024345; increase in AIC = 32, 128,
15 for VCY, current, and average HIV-RNA, respectively, for
TABLE 2. The Effect of Initiation Compared With Deferring cART on Time to AIDS/Death by VCY Alone by CD4 Cell Count Strata
($350, $500 Cells/mm3)
All Patients CD4 ‡ 350 Cells/mm3 CD4 ‡ 500 Cells/mm3
Events,
N HR (95% CI) P, AIC
Events,
N HR (95% CI) P, AIC
Events,
N HR (95% CI) P
VCY, copy-
years/mL
,10,000 198 1.10 (0.74 to 1.63) 0.001* 181 1.04 (0.63 to 1.73) 0.51* 138 0.81 (0.36 to 1.80) 0.56*
10,000–20,000 202 0.91 (0.57 to 1.46) ,0.001† 175 0.79 (0.40 to 1.58) 0.11† 116 0.96 (0.37 to 2.52) 0.09†
20,000–50,000 260 0.69 (0.50 to 0.94) 230,115.30‡ 227 0.88 (0.61 to 1.29) 186,803.80‡ 166 0.70 (0.37 to 1.31) 113,258.00‡
50,000–100,000 242 0.56 (0.40 to 0.80) 206 0.60 (0.36 to 1.01) 146 0.45 (0.18 to 1.09)
.100,000 225 0.44 (0.35 to 0.55) 182 0.68 (0.49 to 0.94) 117 0.41 (0.19 to 0.87)
Current HIV-RNA,
copies/mL
,10,000 180 1.14 (0.81 to 1.61) 0.001* 167 1.37 (0.89 to 2.09) 0.03* 161 0.86 (0.46 to 1.61)§ 0.40*
10,000–20,000 ʇ 140 0.63 (0.36 to 1.08) ,0.001† 121 0.54 (0.22 to 1.33) 0.08† — 0.08†
20,000–50,000 211 0.53 (0.37 to 0.76) 230,353.40‡ 182 0.55 (0.34 to 0.89) 187,014.80‡ 132 0.58 (0.28 to 1.23) 113,454.30‡
50,000–100,000 202 0.62 (0.45 to 0.86) 163 0.80 (0.57 to 1.25) 107 0.61 (0.28 to 1.31)
.100,000 202 0.45 (0.36 to 0.57) 195 0.65 (0.47 to 0.89) 120 0.38 (0.19 to 0.77)
*p-heterogeneity (df = 4).
†p-trend (df = 1).
‡AIC, Akaike information criterion.
§By chance, there were no failures among initiators in the CD4 $500 cells per cubic millimeter, VCY 10,000–20,000 category, so this category is ,20,000 copies per milliliter.
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copy-years, current, average, and maximum HIV-RNA,
respectively). In the CD4 $500 cells per cubic millimeter
strata, VCY gave the best model ﬁt (minimum AIC =
113,258.00, increase in AIC = 196, 84, for current, average,
and maximum HIV-RNA, respectively).
DISCUSSION
Pooling CD4 cell count strata, there is a beneﬁt of
initiating cART as the cumulative and absolute HIV-RNA
increases, with beneﬁts observed as the total VCY exceeds
approximately 17,500 copy-years/mL. What is of clinical
interest, however, is whether there is beneﬁt of immediate
cART initiation in individuals with healthy immune systems
(CD4 $500 cells per cubic millimeter) and high levels of
viremia. Among individuals with CD4 $500 cells per cubic
millimeter, we found a modest beneﬁt of earlier cART
initiation for those with high cumulative and absolute HIV-
RNA .100,000 copy-years/mL and copies per milliliter,
associated with reducing risk of AIDS/death by 59% (13%–
81%) and 62% (23%–81%). Our results support the recent
evidence from the START trial28 which found serious illness
or death was reduced by 53% among those treated immedi-
ately vs. waiting to initiate until CD4 cell count dropped
below 350 cells per cubic millimeter.13
All measures of viremia showed consistent and similar
results with an increased beneﬁt of cART initiation with
increasing VCY. Among the pooled and separate CD4 cell
count strata, there was not a single viremia measure that
consistently showed best model ﬁt using AIC. VCY ﬁts best
when pooling CD4 and in the CD4 $350 cells per cubic
millimeter strata, whereas average viremia ﬁts best in the CD4
,350 cells per cubic millimeter strata. Although VCY
incorporates cumulative HIV burden, it requires frequent
HIV-RNA measurements from the start of infection, which
are not available in most HIV-positive individuals. Even if such
measurements are available, cumulative viremia is difﬁcult and
time-consuming to calculate. Average and maximum HIV-RNA
also require frequent measurements from seroconversion, so too
are not relevant for most HIV-positive individuals. Current
HIV-RNA, however, is a measure that is easily obtained from
all HIV-positive individuals and is therefore of greatest
clinical relevance.
Although observational studies are not designed to
inform the “when to start” question, we provide evidence that
cART initiation is beneﬁcial when CD4 cell counts fall below
350 cells per cubic millimeter, supporting other observational
studies.14,29–31 The START trial has recently reported a modest
absolute risk reduction of AIDS, other serious illnesses, and
death for cART initiation at CD4 cell counts above 500 cells
per cubic millimeter11 compared with deferring initiation to
CD4 below 350 cells per cubic millimeter.13 Our analysis,
using data before guidelines recommending immediate cART
initiation, suggests that beneﬁt is likely to be greatest in those
with highest viremia burden and adds to the body of evidence
which informs clinical guidelines.32
We reﬂected the dynamic process of initiating cART by
allowing individuals to contribute information to multiple
trials rather than just considering a single point in time. This
provided estimates of the average beneﬁt of initiating cART
compared with deferring cART at particular levels of CD4
cell counts and cumulative exposure to HIV-RNA. Our
estimates can therefore be used to inform trade-offs between
initiating treatment at varying points in disease progression
compared with the lifelong challenges of initiating therapy,
such as adherence and adverse effects.
The availability of HIV-RNA data from HIV serocon-
version allowed us to investigate when to start treatment based
on a variety of measures of viremia captured during the life
course of HIV infection. Of particular importance, there is
potential for lead-time bias33 when measuring cumulative
exposure to viremia in sero-prevalent cohorts which is
essentially eliminated in this sero-converter study as we have
serial HIV-RNA measurements taken from the date of
seroconversion. This is, therefore, the ﬁrst study, to our
knowledge, that has compared the beneﬁt of cART initiation
FIGURE 2. The effect of initiating
compared with deferring cART on
time to AIDS/death by VCY and CD4
cell count modeled continuously
with 3 knot splines using the CAS-
CADE data set.
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by these levels of viremia in combination with CD4 cell count.
Nevertheless, despite nearly 10,000 seroconverters being
included, we were not able to assess the impact of initiating
versus deferring within the CD4 strata where decisions on
whether cART should be initiated have previously been most
controversial (CD4 .350 cells/mm3).
In addition to AIDS and death, there are several other
non–AIDS deﬁning conditions that can affect morbidity and
mortality. Increased exposure to viremia has been shown to
be associated with cardiovascular disease,34 multimorbidity,35
and AIDS and non-AIDS malignancies,5,36,37 so had these
data been available, our estimates could have shown a stronger
beneﬁt of cART initiation. CASCADE does not currently
collect data on non–AIDS conditions.
Like all observational studies, our estimates rely on the
assumption of no unmeasured confounding. We adjusted for
some of the most important factors in deciding when to
initiate therapy, but it is possible that other unmeasured
factors, such as comorbidities or likelihood of adherence,
played a role in the initiation of cART in our population. The
HRs above one for cART initiation versus deferred treatment,
albeit with wide conﬁdence intervals, in the group with low
current HIV-RNA suggest we may lack information on some
confounders; this could be a particular concern among those
with a CD4 count $350 cells per cubic millimeter, a group
for which not all treatment guidelines recommended initiation
of cART during the study period.
It is unlikely that randomized evidence will ever be
available on when to initiate cART by these measures of
viremia, so applying robust statistical methods to large
observational data sets presented here will likely provide
the best evidence that will ever be available. Our data suggest
that deferring cART in an individual unwilling or unable to
start treatment immediately may not impact the risk of AIDS/
death provided a healthy CD4 cell count ($350, 500 cells/
mm3) and low VCY (,50,000 copy-years/mL) are main-
tained. However, we found consistently that AIDS and death
were delayed among those who initiated treatment with CD4
cell counts $350 cells per cubic millimeter and VCY
.100,000 copy-years/mL.
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